7-bromo-3-chloro-5'H-spiro[chromeno[2,3-c]pyridine-5,4'-oxazol]-2'-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 7-bromo-3-chloro-5'H-spiro[chromeno[2,3-c]pyridine-5,4'-oxazol]-2'-amine
• 英文别名: 7'-bromo-3'-chlorospiro[5H-1,3-oxazole-4,5'-chromeno[2,3-c]pyridine]-2-amine
• 化学式: C₁₄H₉BrClN₃O₂
• 分子量: 366.601
• InChiKey: OTUUMMCCCZSHMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  69.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-bromo-3-chloro-5'H-spiro[chromeno[2,3-c]pyridine-5,4'-oxazol]-2'-amine 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium phosphate 、 四(三苯基膦)钯 、 二氯双[二叔丁基-(4-二甲基氨基苯基)膦]钯(II) 、 potassium acetate 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 6.0h， 生成 (S)-3-(2-fluoropyridin-4-yl)-7-(5-(prop-1-ynyl)pyridin-3-yl)-5'H-spiro[chromeno[2,3-c]pyridine-5,4'-oxazol]-2'-amine
  参考文献：
  名称：

  Development of 2-aminooxazoline 3-azaxanthene β-amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D

  摘要：

  我们报告了一种口服有效的3-aza-aminooxazoline-BACE1抑制剂的发现，该抑制剂对CatD具有180000倍的选择性，并且在早期筛选的大鼠毒理学研究中没有视网膜影响。

  DOI：

  10.1039/c7md00106a
• 作为产物：
  描述：

  2,5-二溴苯甲酸 在 (CuOTf)*toluene 、 碘 、 4-甲基苯磺酸吡啶 、 caesium carbonate 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 反应 44.0h， 生成 7-bromo-3-chloro-5'H-spiro[chromeno[2,3-c]pyridine-5,4'-oxazol]-2'-amine
  参考文献：
  名称：

  Development of 2-aminooxazoline 3-azaxanthene β-amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D

  摘要：

  我们报告了一种口服有效的3-aza-aminooxazoline-BACE1抑制剂的发现，该抑制剂对CatD具有180000倍的选择性，并且在早期筛选的大鼠毒理学研究中没有视网膜影响。

  DOI：

  10.1039/c7md00106a

文献信息

• [EN] SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE<br/>[FR] COMPOSÉS CYCLIQUES SPIRO-TÉTRACYCLIQUES UTILES EN TANT QUE MODULATEURS DE LA BÊTA-SÉCRÉTASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2010030954A1

  公开（公告）日：2010-03-18

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula (I); wherein A1, A2, A3, A4, A5, A6, T1, T2, W, X, Y and Z of Formula (I) are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula (I).

  本发明涉及一类新的化合物，用于调节β-分泌酶酶活性，并用于治疗β-分泌酶介导的疾病，包括阿尔茨海默病（AD）及相关疾病。在一种实施例中，这些化合物具有一般的化学式（I）；其中化学式（I）中的A1、A2、A3、A4、A5、A6、T1、T2、W、X、Y和Z在此处定义。该发明还包括将这些化合物用于制备用于治疗与β-分泌酶蛋白活性相关的疾病和症状的药物组合物。这些疾病包括例如阿尔茨海默病、认知缺陷、认知障碍、精神分裂症以及与大脑斑块的形成和/或沉积相关和/或由此引起的其他中枢神经系统疾病。该发明还涵盖了化学式I的进一步实施例、中间体和用于制备化合物的有用过程。
• [EN] SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS<br/>[FR] COMPOSÉS SPIRO TÉTRACYCLIQUES EN TANT QUE MODULATEURS DE LA BÉTA-SÉCRÉTASE
  申请人：AMGEN INC

  公开号：WO2011115938A1

  公开（公告）日：2011-09-22

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and other related conditions. In one embodiment, the compounds have a general Formula (I) wherein A1, A2, A3, A4, A5, A6, R2, R7, X and Y of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

  本发明涉及一类新的化合物，用于调节Beta-分泌酶酶活性，治疗由Beta-分泌酶介导的疾病，包括阿尔茨海默病（AD）和其他相关疾病。在一个实施例中，这些化合物具有通用的化学式（I），其中化学式I中的A1、A2、A3、A4、A5、A6、R2、R7、X和Y已在此定义。该发明还包括将这些化合物用于制备药物组合物，用于治疗与β-分泌酶蛋白活性相关的疾病和症状，如阿尔茨海默病、认知缺陷、认知障碍、精神分裂症以及与大脑斑块形成和/或沉积有关的其他中枢神经系统疾病。该发明还涉及化学式I的进一步实施例、中间体和用于制备化合物的过程。
• SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE
  申请人：White Ryan

  公开号：US20100087429A1

  公开（公告）日：2010-04-08

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , T 1 , T 2 , W, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

  本发明涉及一类新化合物，可用于调节Beta-分泌酶酶活性和治疗Beta-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关病症。其中，一种实施方式是化合物具有通式I，其中通式I中的A1、A2、A3、A4、A5、A6、T1、T2、W、X、Y和Z的定义在此。本发明还包括这些化合物在制备用于治疗与beta-分泌酶蛋白活性相关的疾病和病症的药物组合物中的使用，包括阿尔茨海默病、认知障碍、认知损伤、精神分裂症和其他与大脑斑块的形成和/或沉积相关和/或由此引起的中枢神经系统病症。本发明还包括通式I的进一步实施方式、中间体和制备通式I化合物的有用过程。
• SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE
  申请人：CHENG Yuan

  公开号：US20110251190A1

  公开（公告）日：2011-10-13

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and other related conditions. In one embodiment, the compounds have a general Formula I wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , R 2 , R 7 , X and Y of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

  本发明涉及一类新的化合物，可用于调节β-分泌酶酶活性和治疗β-分泌酶介导的疾病，包括阿尔茨海默病（AD）和其他相关疾病。在一种实施例中，所述化合物具有一般的I式，其中I式中的A1，A2，A3，A4，A5，A6，R2，R7，X和Y已在此定义。本发明还包括使用这些化合物于制备药物组合物，用于治疗与β-分泌酶蛋白活性相关的疾病和症状，包括例如阿尔茨海默病、认知缺陷、认知障碍、精神分裂症和其他与大脑斑块形成和/或沉积相关和/或由此引起的中枢神经系统疾病。本发明还包括I式的进一步实施例、中间体和制备I式化合物的有用工艺。
• Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer’s disease
  作者：Jian Jeffrey Chen、Qingyian Liu、Chester Yuan、Vijay Gore、Patricia Lopez、Vu Ma、Albert Amegadzie、Wenyuan Qian、Ted C. Judd、Ana E. Minatti、James Brown、Yuan Cheng、May Xue、Wenge Zhong、Thomas A. Dineen、Oleg Epstein、Jason Human、Charles Kreiman、Isaac Marx、Matthew M. Weiss、Stephen A. Hitchcock、Timothy S. Powers、Kui Chen、Paul H. Wen、Douglas A. Whittington、Alan C. Cheng、Michael D. Bartberger、Dean Hickman、Jonathan A. Werner、Hugo M. Vargas、Nancy E. Everds、Steven L. Vonderfecht、Robert T. Dunn、Stephen Wood、Robert T. Fremeau、Ryan D. White、Vinod F. Patel

  DOI：10.1016/j.bmcl.2014.12.092

  日期：2015.2

  The beta-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) is one of the most hotly pursued targets for the treatment of Alzheimer's disease. We used a structure-and property-based drug design approach to identify 2-aminooxazoline 3-azaxanthenes as potent BACE1 inhibitors which significantly reduced CSF and brain Ab levels in a rat pharmacodynamic model. Compared to the initial lead 2, compound 28 exhibited reduced potential for QTc prolongation in a non-human primate cardiovascular safety model. (C) 2015 Elsevier Ltd. All rights reserved.